R906289
Rigel
['mds']
congress | #asco23 | guillermo garcia-manero presented the phase i study of irak 1/4 inhibitor (r289) in pts with refractory/resistant lr-mds. the study is currently recruiting at 9 us sites &amp; will evaluate the tolerability &amp; preliminary efficacy of r289. #mdssm 
Lifting levels of knowledge in myelodysplastic syndromes (#MDS). A global online platform providing latest treatment options and medical information. #mdssm